Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Stem cells have been investigated as a potential treatment for Chronic Obstructive Pulmonary Disease (COPD) due to their regenerative and immunomodulatory properties. Scientific interest in this area is relatively recent and primarily centers on the idea that stem cells, particularly mesenchymal stem cells (MSCs), can help repair or regenerate damaged lung tissue and modulate the chronic inflammation that characterizes COPD.

Several preclinical studies in animal models have shown that administration of MSCs can reduce lung inflammation, improve lung function, and promote tissue repair. Early-phase human clinical trials have demonstrated that stem cell therapy is generally safe and well-tolerated in COPD patients. For example, small-scale studies have reported improvements in quality of life and some functional lung parameters following MSC therapy. However, these trials have been limited by small sample sizes, lack of long-term data, and inconsistent outcomes.

To date, there is no large, definitive clinical trial demonstrating that stem cell therapy significantly alters the course of COPD or provides substantial clinical benefit over standard treatments. Most clinical guidelines consider stem cell use for COPD experimental and recommend it only within clinical trial settings. Therefore, while there is scientific rationale and some preliminary evidence, the overall strength of scientific support is modest, and more rigorous research is needed to confirm effectiveness.

More about Stem Cells
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by Stem Cells

Products containing Stem Cells